APVO

Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of cancer. Headquartered in Seattle, Washington, the company specializes in creating molecules designed to harness the immune system to attack tumors. Aptevo's lead product candidate, APVO436, is a bispecific antibody designed to bind to CD123 and CD3, intended for treating acute myeloid leukemia and other CD123-positive hematologic malignancies. The company's pipeline also includes APVO603, a dual agonist fusion protein targeting 4-1BB and OX40, being developed for solid tumors. Aptevo operates through a flexible and cost-efficient business model, utilizing partnerships and collaborations to advance its clinical programs while managing expenses. The company emerged from a 2016 spin-off from Emergent BioSolutions and maintains rights to royalties from Roche's marketed product GAZYVA (obinutuzumab). In recent years, Aptevo has faced financial challenges common to clinical-stage biotechnology firms, including the need for continued capital raises to fund ongoing trials and operations. The company focuses its resources on advancing its most promising therapeutic candidates through clinical development while exploring strategic alternatives and partnership opportunities. As of recent filings, Aptevo employs approximately 15 full-time employees and continues to evaluate its portfolio to maximize shareholder value.